MedTrace Logo

Dexmedetomidine Facilitate Analgesia

NCT04675372 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2021-08-05

No results posted yet for this study

Summary

Pre-clinic evidences showed that DEX produces antinociception by inhibiting the activation of spinal microglia and astrocyte decreasing noxious stimuli evoked release of nociceptive substances and further interrupting the spinal neuron-glia cross talk and regulating the nociceptive transmission under chronic pain condition. in this study, the analgesic efficacy of Dexmedetomidine was evaluated by a new non-invasive nociceptive index (qNOX). In this study, Anagel6000 analgesia monitor was used to quantitatively compare the analgesic efficacy of Dexmedetomidine compared with Midazolam.

Conditions

  • Lower Limb Fracture
  • Nerve Block

Interventions

DRUG

Dexmedetomidine

Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion

DRUG

Midazolam

Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam

Sponsors & Collaborators

  • China International Neuroscience Institution

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-19
Primary Completion
2021-08-01
Completion
2021-08-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04675372 on ClinicalTrials.gov